Business Context and Reporting Period
The provided filing is a Form 10-Q for Neuralstem, Inc., not Palisade Bio, Inc. It covers the three months ended March 31, 2017, and was filed May 10, 2017. Neuralstem was a clinical-stage biopharmaceutical company developing NSI-189, NSI-566, and neural stem-cell and small-molecule technologies for central nervous system disorders.
The filing states that the company completed a 1-for-13 reverse stock split in January 2017 and had 11,899,453 common shares outstanding as of April 30, 2017.
Financial Performance and Position
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Revenue | $2,500 | $2,500 | Flat |
| Research and development expense | $2.902 million | $3.066 million | Down 5% |
| General and administrative expense | $1.332 million | $3.171 million | Down 58% |
| Total operating expense | $4.235 million | $6.236 million | Down 32% |
| Operating loss | $4.232 million | $6.234 million | Improved |
| Net loss | $7.567 million | $6.606 million | Loss increased |
| Basic and diluted loss per share | $0.68 | $0.93 | Improved per share, partly due to higher share count |
| Net cash used in operating activities | $4.436 million | $3.488 million | Use increased 27% |
Revenue was immaterial, consisting of intellectual-property license fees. The operating loss margin was approximately 169,280% of reported revenue, and the net loss margin was approximately 302,690%; these percentages are not economically meaningful because revenue was only $2,500.
At March 31, 2017, cash and cash equivalents were $11.680 million, short-term investments were $5.000 million, and total liquidity was approximately $16.7 million. Total assets were $18.728 million, total liabilities were $8.949 million, and stockholders’ equity was $9.780 million.
Derivative liabilities related to stock warrants were $3.885 million at March 31, 2017. The company recorded a $2.741 million loss from changes in their fair value and $476,000 of warrant-inducement expense during the quarter. Long-term debt had a remaining principal balance of $2.543 million at March 31, 2017 and was paid in full on April 1, 2017.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined $164,000, primarily because of lower employment and internal and external research costs following the May 2016 restructuring, partly offset by a $1.6 million increase in Phase 2 major depressive disorder trial costs.
- General and administrative expense declined $1.838 million, principally because of restructuring-related employment-cost savings and the absence of approximately $407,000 of accelerated option vesting expense recognized in Q1 2016.
- Net loss increased $961,000 despite lower operating expenses because Q1 2017 included $2.741 million of derivative fair-value losses and $476,000 of warrant-inducement expense.
- Operating cash use increased $948,000, primarily because the company paid accrued bonuses and accounts payable in Q1 2017.
- Financing activities provided $922,000 in Q1 2017, including approximately $2.2 million from warrant exercises and $50,000 from common-stock sales, partly offset by $1.317 million of debt payments. Q1 2016 financing activities used $1.097 million.
- Cash declined $3.514 million during Q1 2017 to $11.680 million, compared with a $2.904 million increase in Q1 2016, when the company received approximately $7.5 million from maturing short-term investments.
Guidance, Outlook, Risks, and Unusual Items
- Management expected NSI-189 Phase 2 major depressive disorder results in the third quarter of 2017, approximately four months ahead of the original schedule. The trial randomized 220 subjects, and the last subject was enrolled in February 2017.
- Management estimated average monthly cash burn of approximately $2.1 million in Q2 2017, $0.8 million in the second half of 2017, and $0.6 million in the first half of 2018. Based on these assumptions, existing liquidity was expected to fund operations into the third quarter of 2018, including the debt repayment.
- The company stated that it would require additional capital and had no committed future funding. Potential sources included equity or debt offerings, licensing arrangements, collaborations, and grants.
- Failure to obtain financing could require the company to delay, reduce, or discontinue research programs and clinical trials, cease operations, or file for bankruptcy.
- The company had no approved commercial products and generated no revenue from product sales. Regulatory approval, successful clinical outcomes, manufacturing, intellectual-property protection, reimbursement, and market acceptance remained uncertain.
- Warrant exercises in March and April 2017 generated approximately $2.75 million in gross proceeds in total. The related inducement warrants and registration obligations may cause future dilution and potential cash damages if registration requirements are not met.
- The CFO and principal accounting officer left the company effective April 30, 2017; Richard Daly became interim principal financial and accounting officer.
- The filing states that disclosure controls were effective as of March 31, 2017 and that no material changes in internal control over financial reporting occurred during the quarter.
Important Facts for Investors to Verify
- Issuer identity: Confirm whether the intended filing was Neuralstem, Inc.; the supplied metadata identifies Palisade Bio, Inc.
- Clinical milestones: Verify the timing and results of the NSI-189 Phase 2 study and the status of NSI-566 trials.
- Liquidity and financing: Reconcile the reported cash runway with actual subsequent cash burn, financing proceeds, and any later going-concern disclosures.
- Debt repayment: Confirm the April 1, 2017 payment of the remaining $2.543 million principal balance and any related fees.
- Warrant dilution: Review outstanding warrants, derivative-liability valuations, inducement warrants, and subsequent exercises.
- Capital needs: Determine whether additional equity, debt, licensing, or collaboration financing was obtained and assess resulting dilution.
- Management transition: Review subsequent filings concerning the CFO departure and interim finance leadership.
- Regulatory and listing status: Confirm continued Nasdaq compliance and the regulatory status of the company’s clinical programs.